Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like (Philadelphia chromosome like) B‐acute lymphoblastic leukemia

  title={Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like (Philadelphia chromosome like) B‐acute lymphoblastic leukemia},
  author={Theodore Anagnostou and Ryan A. Knudson and Kathryn E. Pearce and Reid G. Meyer and Beth A. Pitel and Jess F Peterson and Linda B. Baughn and Kaaren K. Reichard and Rhett P Ketterling and Sara M. Kloft‐Nelson and Darlene L. Knutson and Shakila P. Khan and Naseema Gangat and Mark R. Litzow and William J. Hogan and Alexandra P. Wolanskyj and Aref Al-Kali and Kebede H. Begna and Michelle A Elliott and Animesh D Pardanani and James M. Foran and Mithun Vinod Shah and Ayalew Tefferi and Hassan B Alkhateeb and Kevin C. Halling and Vilmarie Rodriguez and Patricia T Greipp and Mrinal M. Patnaik},
  journal={American Journal of Hematology},
Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee Department of Pediatrics, Division of Pediatric Neurology, Vanderbilt University Medical Center, Nashville, Tennessee Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee Department of Pediatrics, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee Department of Internal Medicine, Division of Hematology… 
Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes
This study identifies patients with Ph-like ALL by applying targeted FISH panels on remnant diagnostic leukemia cytogenetic pellets from patients identified and treated at the Mayo Clinic Cancer Center and examines clinical outcomes with a focus on the role of induction therapy, minimal residual disease (MRD) and allo-HCT in comparison to other cytogenetics groups.
Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter
This study showed that Ph-like patients had a lower complete response rate, event-free survival and disease, and the GIMEMA LAL1913 front-line protocol for adults with Ph-negative ALL was assessed in order to assess response to the treatment and prognosis.
Granulocyte colony-stimulating factor acts on lymphoid-biased, short-term hematopoietic stem cells
Children and adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis, and the first report of the MRD-oriented GIMEMA 1913 is reported.


Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
High frequency ofPh-like ALL in adults, an increased frequency of Ph-like All in adults of Hispanic ethnicity, significantly inferior outcomes of adult patients with Ph- like ALL, and significantly worse outcomes in the CRLF2+ subset of Ph -like ALL are shown.
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors.
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
  • S. Hunger, Xiaomin Lu, W. Carroll
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
This study documents ongoing survival improvements for children and adolescents with acute lymphoblastic leukemia, emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.
Central nervous system complications and management in sickle cell disease.
In high-income countries, RCTs have demonstrated that regular blood transfusion therapy (typically monthly) achieves primary stroke prevention in children with SCA and high transcranial Doppler velocities; after at least a year, hydroxycarbamide may be substituted.
Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups
Among patients with acute leukemias, disparities in survival persist between non-Hispanic white people and people of other ethnic or racial groups, and Disparities are increasing in younger Patients with acute myeloblastic leukemia.
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.
The addition of intravenous magnesium did not shorten length of stay, reduce opioid use, or improve quality of life in children hospitalized for sickle cell pain crisis.
ACKNOWLEDGMENTS Current publication is supported in part by grants from the "The Henry J. Predolin Foundation for Research in Leukemia
  • and the Division of Hematology
  • 2015
Patnaik has served on the advisory board for StemLine Pharmaceuticals